tag:blogger.com,1999:blog-6377401824680246858.post6180693590157533583..comments2024-03-05T15:49:16.751+00:00Comments on The SPC blog: Shoot the phoenix, count the cost!roberthttp://www.blogger.com/profile/03575489215896576032noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-6377401824680246858.post-37418395349623344802011-10-27T15:12:10.766+01:002011-10-27T15:12:10.766+01:00Yes, I too am curious as to the answer to Anonymou...Yes, I too am curious as to the answer to Anonymous' question. <br /><br />And perhaps Sophie could also comment on the percentage of innovator pharma companies' turnover typically spent on R&D, with the typical price difference between innovator and generic medicines?<br /><br />I have looked at Sanofi-Aventis' published 2010 financial statements, which I expect are fairly typical. These financial statements reflect R&D expenses at 14,5% of net sales, with "selling and general expenses" at 24,9%. In comparison, the average price difference between innovator and generic products is a lot more than 14,5%!<br /><br />I am a little puzzled by Sophie's comment about reported profits getting ploughed back into R&D, rather than being distributed to shareholders. Is the R&D to which Sophie refers additional to the R&D reflected as an expense in the financial statements?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-6377401824680246858.post-78941394132266621922011-10-25T07:36:05.030+01:002011-10-25T07:36:05.030+01:00I would like to know what percentage of the profit...I would like to know what percentage of the profit made by a pharmaceutical company is actually invested in research and how much goes into marketing. Sophie, please comment!Anonymousnoreply@blogger.com